Abstract:Background The pentose phosphate pathway (PPP) plays a crucial role in the material and energy metabolism in cancer cells. Targeting 6-phosphogluconate dehydrogenase (6PGD), the rate-limiting enzyme in the PPP metabolic process, to inhibit cellular metabolism is an effective anticancer strategy. In our previous study, we have preliminarily demonstrated that gambogic acid (GA) induced cancer cell death by inhibiting 6PGD and suppressing PPP at the cellular level. However, it is unclear whether GA could suppress cancer cell growth by inhibiting PPP pathway in mouse model. Purpose This study aimed to confirm that GA as a covalent inhibitor of 6PGD protein and to validate that GA suppresses cancer cell growth by inhibiting the PPP pathway in a mouse model. Methods Cell viability was detected by CCK-8 assays as well as flow cytometry. The protein targets of GA were identified using a chemical probe and activity-based protein profiling (ABPP) technology. The target validation was performed by in-gel fluorescence assay, the Cellular Thermal Shift Assay (CETSA). A lung cancer mouse model was constructed to test the anticancer activity of GA. RNA sequencing was performed to analyze the global effect of GA on gene expression. Results The chemical probe of GA exhibited high biological activity in vitro . 6PGD was identified as one of the binding proteins of GA by ABPP. Our findings revealed a direct interaction between GA and 6PGD. We also found that the anti-cancer activity of GA depended on reactive oxygen species (ROS), as evidenced by experiments on cells with 6PGD knocked down. More importantly, GA could effectively reduce the production of the two major metabolites of the PPP in lung tissue and inhibit cancer cell growth in the mouse model. Finally, RNA sequencing data suggested that GA treatment significantly regulated apoptosis and hypoxia-related physiological processes. Conclusion These results demonstrated that GA was a covalent inhibitor of 6PGD protein. GA effectively suppressed cancer cell growth by inhibiting the PPP pathway without causing significant side effects in the mouse model. Our study provides in vivo evidence that elucidates the anticancer mechanism of GA, which involves the inhibition of 6PGD and modulation of cellular metabolic processes.

General Pharmacological Properties, Developmental Toxicity, and Analgesic Activity of Gambogic Acid, a Novel Natural Anticancer Agent

Gambogic Acid Inhibits LPS-induced Macrophage Pro-Inflammatory Cytokine Production Mainly Through Suppression of the P38 Pathway

Gambogic acid is a novel anti-cancer agent that inhibits cell proliferation, angiogenesis and metastasis.

Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells.

Inhibition of glioblastoma growth and angiogenesis by gambogic acid: an in vitro and in vivo study.

Gambogic Acid as a Candidate for Cancer Therapy: A Review

Anti-Invasive Effect Of Gambogic Acid In Mda-Mb-231 Human Breast Carcinoma Cells

Anti-tumor Effect of Gambogenic Acid and Its Effect on CYP2C and CYP3A after Oral Administration.

Proteomic and Bioinformatic Analyses of Possible Target-Related Proteins of Gambogic Acid in Human Breast Carcinoma MDA-MB-231 Cells.

GA3, a New Gambogic Acid Derivative, Exhibits Potent Antitumor Activities in Vitro Via Apoptosis-Involved Mechanisms

Enhancement of anticancer efficacy of chemotherapeutics by gambogic acid against gastric cancer cells.

Gambogic acid-induced autophagy in nonsmall cell lung cancer NCI-H441 cells through a reactive oxygen species pathway

Pharmacolcinetics, Tissue Distribution, Excretion, and Metabolism of A Novel Antitumor Agent, Gambogenic Acid, in Rats

Research Progress in the Field of Gambogic Acid and Its Derivatives as Antineoplastic Drugs

Anticancer Effect and Apoptosis Induction of Gambogic Acid in Human Leukemia Cell Line K562 In Vitro

Gambogic acid exhibits promising anticancer activity by inhibiting the pentose phosphate pathway in lung cancer mouse model

Gambogic acid induces apoptosis of lung cancer H1975 cells by activating JNK signaling pathway and upregulating ROS

Synthesis and Biological Evaluation of Novel Spin Labeled 18Β-Glycyrrhetinic Acid Derivatives

Antitumor Activity of Gambogic Acid on NCI-H1993 Xenografts Via MET Signaling Pathway Downregulation

Anticancer activity and underlying mechanism of neogambogic acid

Gambogic acid impairs tumor angiogenesis by targeting YAP/STAT3 signaling axis.